Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for PLX4032

1 Open Trial

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCMD16103

    07/10/2017

    My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents


    Print this page for your doctor